Akcea Therapeutics Inc
Most Recent
Company & Industry Overviews.Why Alnylam Pharmaceuticals Stock Rose ~16% Yesterday
Yesterday, Alnylam Pharmaceuticals (ALNY) closed the day ~16.3% higher than the previous day’s closing price.
Company & Industry Overviews.Why Citius Pharmaceuticals Stock Rose 31% in Week Ended July 13
In the week ended July 13, Citius Pharmaceuticals (CTXR) stock rose 31% to $3.09, from $2.35 on July 6. Since July 10, it has grown consistently.
Company & Industry Overviews.Must-Know Developments for Ionis Pharmaceuticals in 2018
On February 20, 2018, Ionis announced that the company has licensed the drug IONIS-AZ5-2.5Rx to AstraZeneca (AZN).
Company & Industry Overviews.Key Updates on Akcea Therapeutics’ Volanesorsen
Ionis Pharmaceuticals’ (IONS) Volanesorsen is a drug for the treatment of familial chylomicronemia syndrome (or FCS) and familial partial lipodystrophy (or FPL).
Company & Industry Overviews.Exploring the Financial Performance of Akcea Therapeutics
In 2017, Akcea Therapeutics (AKCA) generated total revenue of $55.2 million.
Company & Industry Overviews.A Look at Akcea Therapeutics’ Product Pipeline
Akcea Therapeutics’ (AKCA) Volanesorsen is currently under review in the United States, the European Union, and Canada.
Company & Industry Overviews.Analysts’ Recommendations for Akcea and Its Peers in March
Akcea Therapeutics is currently advancing a mature pipeline of four novel drugs with the potential to treat many cardiometabolic diseases.